platoseedplatoseed
Using CRISPR to find treatments for cancer and inflammation
Algen is using CRISPR to uncover disease-driving RNA messages to find treatments for cancer, inflammation and diseases with high unmet needs. We are harnessing the power of CRISPR and machine learning to find first-in-class drugs that modulate RNA messages at single-cell resolution. Algen's founders are bioengineer from Jennifer Doudna Lab and biotech commercialization expert, teamed up with experienced pharmaceutical executives.
Algen Biotechnologies uses CRISPR-based gene modulation combined with AI to accelerate therapeutic drug discovery, aiming to identify disease drivers and translate them into human-centric therapeutic endpoints. The company leverages a proprietary CRISPR system and deep learning models to predict RNA signaling networks during disease progression.
AlgenCRISPR is a proprietary, next-generation CRISPR gene-modulation system that enables robust, fine-tuned and precise gene modulation. It powers the AlgenBrain platform, which industrializes single-cell gene modulation to drive toward meaningful therapeutic endpoints. AlgenBrain employs proprietary AI models trained on dynamic, real-time gene expression data across disease progression to illuminate disease-driving RNA signaling pathways and extract actionable insights for drug discovery.
Who it’s for: Biotech and pharmaceutical companies seeking AI-enabled CRISPR-based drug discovery, with a focus on cancer and inflammatory diseases, and organizations looking to accelerate therapeutic development using gene modulation and AI.
Company profile referencing high-value deals and partnerships (e.g., AstraZeneca) and active press coverage indicating traction and fundraising signals
Formerly “Inc” · why startups rename →
Unleashing the potential of DNA and RNA based therapies using AI
We create activating antibodies to treat diseases others can’t.
